New Cellectis video showcases allogeneic CAR-T tech; AbbVie reports fresh advance with hep C combo;

@FierceBiotech: Chris Viehbacher explains: "If I had $2 billion to invest ..." More | Follow @FierceBiotech

@JohnCFierce: Cool new video on Cellectis's allogeneic approach to T cells. It looks so easy... Watch | Follow @JohnCFierce

@DamianFierce: Analyst on $ADHD call: "congrats on these interesting observations." Their drug was outperformed by placebo, dude. | Follow @DamianFierce

> The race to develop the world's best CAR-T therapy for cancer has inspired some fancy marketing efforts on behalf of some of the leaders in the field. Case in point: France's Cellectis, which is developing an R&D hub in Manhattan, has unveiled a cool new 2-minute video which illustrates how it plans to use TALEN gene editing tech to create allogeneic, or off-the-shelf, engineered T cell treatments. Keep in mind, though, that while Cellectis's approach has helped inspire a big IPO for the company, the company is also quick to acknowledge that it's only be tried in animals so far. The first human study lies ahead. Video

> AbbVie ($ABBV) reported fresh progress with its hep C combo Viekira Pak. Investigators say the combo was effective whether or not it was used with ribavirin. Story

> Australian stem cell company Genea Biocells is expanding its operations to the United States with plans to open a new facility in San Diego. Release

Medical Device News

@FierceMedDev: Broad Institute bags $20M for drug-resistant TB research. More from FierceDiagnostics | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Medtronic strikes back with FDA approval of its third-gen TAVR. Report | Follow @VarunSaxena2

@EmilyWFierce: Cue the screaming fans: Nick Jonas signs up with Dexcom diabetes effort. FiercePharmaMarketing story | Follow @EmilyWFierce

> The Esophageal Cooling Device gets FDA's rare de novo clearance for innovative devices. Article

> Philips ($PHG) readies launch of smart device-based ultrasound device, app. Story

Pharma News

@FiercePharma: India's Kumar eyes a one-stop shop on pharmaceuticals. FiercePharmaAsia story | Follow @FiercePharma

@EricPFierce: See which companies had the most Class I recalls in recent years. Feature from FiercePharmaManufacturing | Follow @EricPFierce

> Hospira ($HSP) gets FDA OK for massive India plant from which Pfizer ($PFE) will reap the rewards. Story

> Report: Novo ($NVO), Sanofi ($SNY) and Merck ($MRK) dominate global diabetes market. More

Biotech Research News

> Team spotlights new evidence that Parkinson's starts in the gut. Story

> Allied-Bristol JV picks up rights to Harvard's work on traditional Chinese remedy. News

> Experimental prostate cancer combo shows promise in case studies. Report

> Purdue group finds Achilles' heel for MERS. Item

> Investigators say they've designed a new-and-improved antibiotic. Article

Diagnostics News

> Qiagen ($QGEN) to partner with Japan's Hitachi on molecular testing. More

> Broad Institute bags $20M for drug-resistant TB research. Item

> Advanced Cell Diagnostics receives $22M to develop its RNA biomarker tech. News

> Siemens snags FDA approval for HIV combo test. Story

> Biodesix brings Series E to $38M for blood-based lung cancer Dx. Article

Pharma Marketing News

> Another AZ exec jumps ship for CEO job at smaller drugmaker. Item

> Novartis ($NVS) playing catch-up in cancer? Not us, says top oncology exec. Story

> Has Lundbeck failed to sharpen Brintellix's marketing edge with payers? More

> Call it Allergan ($AGN), call it a 'growth pharma.' Just don't call it Big Pharma. Article

> Got game? Pharma's moving into gamification but needs to drop the bribes. Report

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.